MA31983B1 - Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12 - Google Patents

Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12

Info

Publication number
MA31983B1
MA31983B1 MA32897A MA32897A MA31983B1 MA 31983 B1 MA31983 B1 MA 31983B1 MA 32897 A MA32897 A MA 32897A MA 32897 A MA32897 A MA 32897A MA 31983 B1 MA31983 B1 MA 31983B1
Authority
MA
Morocco
Prior art keywords
phosphonic acid
antagonists
receptor
acid derivatives
vascular
Prior art date
Application number
MA32897A
Other languages
Arabic (ar)
English (en)
Inventor
Eva Caroff
Kurt Hilpert
Francis Hubler
Emmanuel Meyer
Dorte Renneberg
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40445499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31983(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31983B1 publication Critical patent/MA31983B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne les dérivés de 2-phényl-pyrimidine contenant un motif d'acide phosphonique et leur utilisation comme antagonistes du récepteur p2y12 dans le traitement et/ou la prévention de maladies vasculaires périphériques, viscérales, hépatiques et vasculaires rénales, cardiovasculaires et cérébrovasculaires ou de troubles associés à l'agrégation plaquettaire, y compris la thrombose chez les humains et les autres mammifères
MA32897A 2007-11-29 2010-06-08 Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12 MA31983B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054850 2007-11-29
PCT/IB2008/055002 WO2009069100A1 (fr) 2007-11-29 2008-11-28 Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12

Publications (1)

Publication Number Publication Date
MA31983B1 true MA31983B1 (fr) 2011-01-03

Family

ID=40445499

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32897A MA31983B1 (fr) 2007-11-29 2010-06-08 Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12

Country Status (24)

Country Link
US (1) US8518912B2 (fr)
EP (1) EP2225253B1 (fr)
JP (1) JP4729133B2 (fr)
KR (1) KR101178319B1 (fr)
CN (1) CN101868469B (fr)
AR (1) AR069494A1 (fr)
AU (1) AU2008331163B2 (fr)
BR (1) BRPI0819696B1 (fr)
CA (1) CA2706475C (fr)
CY (1) CY1113151T1 (fr)
DK (1) DK2225253T3 (fr)
ES (1) ES2388958T3 (fr)
HR (1) HRP20120735T1 (fr)
IL (1) IL205947A (fr)
MA (1) MA31983B1 (fr)
MX (1) MX2010005519A (fr)
MY (1) MY153749A (fr)
NZ (1) NZ586445A (fr)
PL (1) PL2225253T3 (fr)
PT (1) PT2225253E (fr)
RU (1) RU2483072C2 (fr)
SI (1) SI2225253T1 (fr)
TW (1) TWI361690B (fr)
WO (1) WO2009069100A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
MX2010004995A (es) 2007-11-29 2010-05-20 Boehringer Ingelheim Int Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazo l-3-carboxilico.
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (fr) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Derives de thiazole et leur utilisation comme antagonistes des recepteurs p2y12
US9539246B2 (en) 2011-08-30 2017-01-10 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
EP3182971A4 (fr) 2014-08-21 2018-04-25 SRX Cardio, LLC Composition et procédés d'utilisation de petites molécules en tant que ligands de liaison pour la modulation de l'activité proprotéine convertase subtilisine/protéine kexine de type 9 (pcsk9)
WO2017063757A1 (fr) 2015-10-12 2017-04-20 Polyphor Ag Composés macrocycliques à conformation limitée
WO2017063755A1 (fr) 2015-10-12 2017-04-20 Polyphor Ag Composés macrocycliques à conformation limitée
EP3515924B1 (fr) * 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Formes cristallines
CN106749408A (zh) * 2017-02-09 2017-05-31 广东赛博科技有限公司 一种硝基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
CN106831867A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 一种腈基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
HUE053191T2 (hu) 2017-02-09 2021-06-28 Bayer Ag 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
CN106831868A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 一种胺基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
CN106831866A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 一类烷氧噻吩芳基氧化膦p2y12受体拮抗剂及其用途
CN106831871A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 一类硝基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
CN106831870A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 一类腈基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
CN106831869A (zh) * 2017-02-09 2017-06-13 广东赛博科技有限公司 胺基噻吩芳基氧化膦p2y12受体拮抗剂及其用途
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
EP3713923B1 (fr) 2017-11-21 2021-12-01 Bayer Aktiengesellschaft 2-phénylpyrimidine-4-carboxamides à utiliser en tant qu'inhibiteurs d'ahr
WO2021226559A1 (fr) 2020-05-08 2021-11-11 Tonix Pharmaceuticals, Inc. Composés radioprotecteurs et chimioprotecteurs
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
CN112500354A (zh) * 2020-12-08 2021-03-16 烟台凯博医药科技有限公司 一种4-氯-6-环丙基嘧啶-5-胺的合成方法
MX2024000653A (es) * 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB921252A (en) 1960-03-09 1963-03-20 Erba Carlo Spa New tetracycline derivatives
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US3341585A (en) 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
US3345410A (en) 1966-12-01 1967-10-03 American Cyanamid Co Substituted 7- and/or 9-amino tetracyclines
US3373196A (en) 1967-03-21 1968-03-12 American Cyanamid Co 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines
US3518306A (en) 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US3579579A (en) 1968-04-18 1971-05-18 American Cyanamid Co Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines
GB1469384A (en) 1974-06-25 1977-04-06 Farmaceutici Italia Tetracyclines
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
IT1135476B (it) 1981-02-16 1986-08-20 Brionvega Spa Disposizione per l'orientamento automatico di una antenna in un radioricevitore o televisore per mezzo d'un telecomando
CA2020437A1 (fr) 1989-07-05 1991-01-06 Yoshihide Fuse Derive de cinnamamide
DE122006000058I1 (de) 1991-10-04 2007-01-18 Wyeth Corp 7-Substituierte-9-substituierte Amino-6-Demethyl-6-Deoxy-Tetracycline
US5281628A (en) 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US6693130B2 (en) 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
CA2318580A1 (fr) 1998-01-23 1999-07-29 Mark L. Nelson Composes pharmaceutiquement actifs et procedes d'utilisation correspondants
JP4413429B2 (ja) 1998-06-25 2010-02-10 株式会社グリーンペプタイド サイクロフィリンｂ由来の腫瘍抗原ペプチド
ATE336238T1 (de) 1998-11-18 2006-09-15 Collagenex Pharm Inc Neue 4-dedimethylaminotetracyclinderivate
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
EP2327687A3 (fr) 1999-09-14 2012-08-15 Trustees Of Tufts College Procédé de préparation de tétracyclines substituées avec chimies à base de métaux
US8106225B2 (en) 1999-09-14 2012-01-31 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
AU3105801A (en) 2000-01-24 2001-07-31 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
MXPA02009482A (es) 2000-03-31 2004-05-14 Tufts College Compuestos tetraciclinas sustituidos con grupos 7- y 9- carbamato, urea, tiourea, tiocarbamato y heteroaril-amino.
WO2001087824A2 (fr) 2000-05-15 2001-11-22 Paratek Pharmaceuticals, Inc. Composes tretracycliniques a anneaux condenses, substitues en position 7
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20020128238A1 (en) 2000-06-16 2002-09-12 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20020128237A1 (en) 2000-06-16 2002-09-12 Nelson Mark L. 7-N-substituted phenyl tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
JP4963771B2 (ja) 2000-07-07 2012-06-27 トラスティーズ・オブ・タフツ・カレッジ ７、８および９−置換テトラサイクリン化合物
EA013908B1 (ru) 2000-07-07 2010-08-30 Трастис Оф Тафтс Коллидж Замещенные соединения миноциклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния млекопитающего
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
WO2002072532A1 (fr) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues en position 7,9
WO2002072506A2 (fr) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de 7-pyrollyl tetracycline et procedes d'utilisation associes
JP2004530661A (ja) 2001-03-14 2004-10-07 パラテック ファーマシューティカルズ インコーポレイテッド 抗真菌剤としての置換テトラサイクリン化合物
WO2002072031A2 (fr) 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP1399414B1 (fr) 2001-04-24 2010-01-13 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues destines au traitement de la malaria
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EP2329826A1 (fr) 2001-07-13 2011-06-08 Paratek Pharmaceuticals, Inc. Tetracyclines pour le traitement de la sclérose en plaques
EP2311799A1 (fr) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. Composés de tétracycline 4-dedimethylamino
EP1327903A1 (fr) 2002-01-14 2003-07-16 Alcatel Déphaseur optique de guide d'ondes
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
KR101083498B1 (ko) 2002-03-21 2011-11-16 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
CN1694941A (zh) 2002-09-03 2005-11-09 索尔维先进聚合物有限责任公司 导热液晶聚合物组合物及其制品
DE10241156A1 (de) 2002-09-05 2004-03-18 Infineon Technologies Ag Verfahren zum Herstellen einer integrierten pin-Diode und zugehörige Schaltungsanordnung
CN1720224A (zh) * 2002-10-03 2006-01-11 塔尔基公司 血管平衡剂及其使用方法
CA2503446C (fr) 2002-10-24 2012-12-18 Paratek Pharmaceuticals, Inc. Procedes d'utilisation de composes tetracycline substituee pour moduler l'arn
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
CA2531728A1 (fr) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
WO2005009971A1 (fr) * 2003-07-24 2005-02-03 Astellas Pharma Inc. Derive de quinolone ou sel de ce dernier
CA2553510C (fr) 2004-01-15 2012-09-25 Paratek Pharmaceuticals, Inc. Derives a cycle aromatique a provenant de composes de tetracycline
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) * 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
EP2238127B1 (fr) 2007-12-26 2012-08-15 Sanofi Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (fr) * 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Derives de thiazole et leur utilisation comme antagonistes des recepteurs p2y12

Also Published As

Publication number Publication date
AU2008331163B2 (en) 2014-01-30
CY1113151T1 (el) 2016-04-13
EP2225253B1 (fr) 2012-06-27
NZ586445A (en) 2012-06-29
US8518912B2 (en) 2013-08-27
US20100261678A1 (en) 2010-10-14
WO2009069100A1 (fr) 2009-06-04
ES2388958T3 (es) 2012-10-22
BRPI0819696B1 (pt) 2018-10-23
CA2706475A1 (fr) 2009-06-04
HK1148287A1 (en) 2011-09-02
IL205947A (en) 2015-02-26
MY153749A (en) 2015-03-13
BRPI0819696A2 (pt) 2015-06-16
CA2706475C (fr) 2016-05-03
CN101868469A (zh) 2010-10-20
RU2010126048A (ru) 2012-01-10
BRPI0819696A8 (pt) 2017-12-26
TW200922602A (en) 2009-06-01
EP2225253A1 (fr) 2010-09-08
AU2008331163A1 (en) 2009-06-04
RU2483072C2 (ru) 2013-05-27
HRP20120735T1 (hr) 2012-10-31
CN101868469B (zh) 2014-04-02
JP4729133B2 (ja) 2011-07-20
SI2225253T1 (sl) 2012-09-28
KR20100082366A (ko) 2010-07-16
JP2011505352A (ja) 2011-02-24
KR101178319B1 (ko) 2012-09-07
AR069494A1 (es) 2010-01-27
IL205947A0 (en) 2010-11-30
MX2010005519A (es) 2010-06-11
DK2225253T3 (da) 2012-08-27
PT2225253E (pt) 2012-09-19
PL2225253T3 (pl) 2012-11-30
TWI361690B (en) 2012-04-11

Similar Documents

Publication Publication Date Title
MA31983B1 (fr) Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
MA33260B1 (fr) 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
EP2040713A4 (fr) Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
EP2125855A4 (fr) Procédés et compositions pour le traitement du cancer ou d'autres maladies
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA43116A (fr) Ditosylate de valbénazine et polymorphes associés
EP3955954A4 (fr) Polythérapie pour la modulation de l'homéostasie de l'acide biliaire et le traitement des troubles et de maladies de l'acide biliaire
MA28755B1 (fr) Derives de pyrimidine fusionnes et compositions sur leur base, utilises en tant que modulateurs du recepteur de cxcr3, utiles dans la prevention et le traitement de maladies et troubles inflammatoires ou immunoregulateurs
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
MA50417A (fr) Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang
EP1962601A4 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
EP2091955A4 (fr) Composés d'alcoxy pour le traitement de maladies
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
EP1592689A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
DE60132081D1 (de) ZUBEREITUNG ZUR VORBEUGUNG UND BEHANDLUNG VON GEFÄßKRANKHEITEN
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA30041B1 (fr) Immunoglobulines
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EP2139460A4 (fr) Compositions et procédés permettant le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et des maladies neurologiques apparentées
EP2192920A4 (fr) Procédés et compositions pour le traitement ou la prévention d'une fibrose induite par rayonnement